Dosing of Cyclophosphamide in Patients with Impaired Renal Function
Introduction to Cyclophosphamide Dosing
- The American College of Rheumatology recommends that the dose of cyclophosphamide should be reduced according to age and serum creatinine level, using regimens of 7.5-15 mg/kg per intravenous pulse (maximum 1500 mg) or 1-2 mg/kg/day orally, with specific adjustments to avoid hematologic and infectious toxicity 1, 2.
Dosage Adjustment for Intravenous Pulses
- For ANCA-associated vasculitis and severe kidney disease, recent guidelines establish specific reductions based on renal function and age 1, 2.
Table of Dose Adjustment for IV Pulses
| Age | Creatinine Level | Dose |
|---|---|---|
| <60 years | <300 μmol/L | 15 mg/kg/pulse [1] |
| <60 years | 300-500 μmol/L | 12.5 mg/kg/pulse [1] |
| 60-70 years | <300 μmol/L | 12.5 mg/kg/pulse [1] |
| 60-70 years | 300-500 μmol/L | 10 mg/kg/pulse [1] |
| >70 years | <300 μmol/L | 10 mg/kg/pulse [1] |
| >70 years | 300-500 μmol/L | 7.5 mg/kg/pulse [1] |
Frequency of Administration
- The recommended IV pulse regimen is 15 mg/kg (maximum 1500 mg) initially every 2 weeks, then reduced to every 3 weeks, continuing for 3-6 months for induction of remission 2, 3.
Oral Daily Dosage
- For continuous oral therapy, doses should be adjusted more conservatively 3, 4.
- Standard dose: 1-3 mg/kg/day (maximum 200 mg/day) 4, 3.
Critical Safety Considerations
Mandatory Bladder Protection
- MESNA (2-mercaptoethanesulfonate sodium) is mandatory with IV pulses to prevent hemorrhagic cystitis, which occurs in 6% of patients without protection 3.
Antimicrobial Prophylaxis
- Trimethoprim/sulfamethoxazole 800/160 mg on alternate days or 400/80 mg daily is mandatory for Pneumocystis jirovecii prophylaxis during the entire course of cyclophosphamide or for 6 months after rituximab 2, 3.
Cumulative Dose Limits
- The total cumulative dose should be strictly limited due to the risk of secondary malignancies 3, 5.
- General limit: Do not exceed 36 g of total cumulative dose (preferably <25 g) 5.
- Patients who wish to conceive: Maximum 10 g cumulative 5.
Disease-Specific Context
ANCA-Associated Vasculitis with Creatinine >4 mg/dL
- In severe kidney disease (serum creatinine >4 mg/dL or >354 μmol/L), cyclophosphamide remains the preferred agent over rituximab due to limited data on the latter in this population 6, 2.
Required Monitoring
- During cyclophosphamide treatment, the following monitoring is required: